While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.
The above story is based on materials provided by IOS Press BV. Note: Materials may be edited for content and length.
Cite This Page:
IOS Press BV. "Elusive search for biomarkers in Huntington's disease." ScienceDaily. ScienceDaily, 21 May 2013. <www.sciencedaily.com/releases/2013/05/130520163638.htm>.
IOS Press BV. (2013, May 21). Elusive search for biomarkers in Huntington's disease. ScienceDaily. Retrieved March 12, 2014 from www.sciencedaily.com/releases/2013/05/130520163638.htm
IOS Press BV. "Elusive search for biomarkers in Huntington's disease." ScienceDaily. www.sciencedaily.com/releases/2013/05/130520163638.htm (accessed March 12, 2014).